Skip to content

Probiotic Intervention in Constipation

To Evaluate the Efficacy and Safety of Probiotics in Alleviating Constipation in Adults Through a Randomized, Double-blind, Placebo-controlled Trial

Status
Not yet recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07462494
Enrollment
30
Registered
2026-03-10
Start date
2026-06-10
Completion date
2026-12-30
Last updated
2026-06-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastrointestinal Function

Brief summary

To evaluate the effects of probiotic intervention on gastrointestinal function in patients with constipation after 4 weeks of treatment, and to explore its potential effects on immune status and bone metabolism.

Interventions

DIETARY_SUPPLEMENTGUT99 1

Taken orally once daily for 8 weeks (120B).

DIETARY_SUPPLEMENTPlacebo

Taken orally once daily for 8 weeks.

DIETARY_SUPPLEMENTGUT99 2

Taken orally once daily for 8 weeks (1000B).

Sponsors

Wecare Probiotics Co., Ltd.
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
Yes

Inclusion criteria

1. Aged 18-65 years. 2. Patients with constipation, defined as fewer than three bowel movements per week and/or Bristol Stool Form Scale (BSFS) types 1-2. 3. Able to comply with the study protocol and complete the study procedures. 4. Participants who have voluntarily signed the informed consent form. 5. Participants (including male participants) must have no plans for pregnancy from 14 days before screening until 6 months after the end of the study and must agree to use effective contraception during this period. \-

Exclusion criteria

1. Individuals who have recently taken products with similar functions to the investigational product that may affect the evaluation of study outcomes. 2. Participants who plan to change their dietary habits during the study period. 3. Patients with severe allergies or immunodeficiency. 4. Women who are pregnant, breastfeeding, or planning to become pregnant. 5. Patients with severe diseases of major organs such as the cardiovascular system, lungs, liver, or kidneys, or those with severe metabolic diseases (e.g., diabetes or thyroid disorders), malignant tumors, or severe immune system diseases. 6. Individuals who have used antibiotics within the past two weeks. 7. Individuals with severe psychological or psychiatric disorders. 8. Participants who fail to take the investigational product as required or fail to attend scheduled follow-up visits, resulting in an inability to determine treatment efficacy. 9. Any other participants considered unsuitable for participation in the study by the investigator. \-

Design outcomes

Primary

MeasureTime frameDescription
Changes in stool consistency8 weeksStool consistency will be evaluated using the Bristol Stool Form Scale (BSFS) to assess the improvement of constipation symptoms in patients receiving probiotic intervention.

Contacts

CONTACTYing Jin, Doctor
sunny13211@sina.com13375163966

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jun 10, 2026